Anomer Bio

Anomer Bio is a company headquartered in the United Kingdom. Its most recent tracked round is Pre-Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Anomer Bio is a London-based biotech startup focused on advancing glycoscience by developing synthetic monosaccharides aimed at enhancing immune responses and addressing complex health challenges. The company utilizes a proprietary platform that integrates multi-omics data, Nobel Prize-winning research tools, and clinical trial insights to design synthetic sugar therapeutics targeting glycans directly, with applications in immune and fibrotic diseases.